NCT00007202View on ClinicalTrials.gov

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 2006

Conditions
HIV Infections
Interventions
DRUG

Atazanavir

DRUG

Stavudine

DRUG

Didanosine

Trial Locations (5)

30308

AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS, Atlanta

60612

Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS, Chicago

80262

Univ. of Colorado Health Sciences Ctr. AIEDRP, Denver

60611-3015

Feinberg School of Medicine, HIV/ACTU AIEDRP CRS, Chicago

Unknown

Centro de Referencia Estadual de AIDS AIEDRP, Salvador

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00007202 - Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients | Biotech Hunter | Biotech Hunter